- Home
- QIPT vs ACOG Comparison
QIPT vs ACOG Comparison
Compare QIPT & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QIPT
- ACOG
- Stock Information
- Founded
- QIPT 1993
- ACOG 2000
- Country
- QIPT United States
- ACOG Canada
- Employees
- QIPT N/A
- ACOG N/A
- Industry
- QIPT
- ACOG
- Sector
- QIPT
- ACOG
- Exchange
- QIPT Nasdaq
- ACOG Nasdaq
- Market Cap
- QIPT 92.2M
- ACOG 80.3M
- IPO Year
- QIPT N/A
- ACOG N/A
- Fundamental
- Price
- QIPT $2.66
- ACOG $9.71
- Analyst Decision
- QIPT Buy
- ACOG Strong Buy
- Analyst Count
- QIPT 2
- ACOG 1
- Target Price
- QIPT $3.15
- ACOG $20.00
- AVG Volume (30 Days)
- QIPT 789.4K
- ACOG 73.8K
- Earning Date
- QIPT 08-11-2025
- ACOG 11-14-2025
- Dividend Yield
- QIPT N/A
- ACOG N/A
- EPS Growth
- QIPT N/A
- ACOG N/A
- EPS
- QIPT N/A
- ACOG N/A
- Revenue
- QIPT $238,378,000.00
- ACOG $4,586,341.00
- Revenue This Year
- QIPT N/A
- ACOG N/A
- Revenue Next Year
- QIPT $27.59
- ACOG $149.89
- P/E Ratio
- QIPT N/A
- ACOG N/A
- Revenue Growth
- QIPT N/A
- ACOG N/A
- 52 Week Low
- QIPT $1.35
- ACOG $3.75
- 52 Week High
- QIPT $3.27
- ACOG $11.54
- Technical
- Relative Strength Index (RSI)
- QIPT 65.83
- ACOG 61.90
- Support Level
- QIPT $2.53
- ACOG $8.01
- Resistance Level
- QIPT $2.65
- ACOG $9.86
- Average True Range (ATR)
- QIPT 0.09
- ACOG 0.43
- MACD
- QIPT 0.00
- ACOG 0.22
- Stochastic Oscillator
- QIPT 85.13
- ACOG 91.60
About QIPT Quipt Home Medical Corp.
Quipt Home Medical Corp provides in-home monitoring equipment, supplies, and services to patients. The Company operates in one business segment, which is the sale and rental of medical equipment and related devices. The company's services consist of Daily and Ambulatory Aides, Power Mobility, INR Self-Testing, Respiratory Equipment Rental, Home ventilation, Oxygen Therapy, and Sleep Apnea and PAP Treatment.
About ACOG Alpha Cognition Inc. Common Stock
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.